Daily Stock List
Blacksands Petroleum, Inc. (BSPE)
Today we are reporting on Blacksands Petroleum, Inc. (BSPE), here at the QualityStocks Daily Newsletter.
Blacksands Petroleum, Inc. engages in the acquisition, exploration and development of conventional and unconventional oil and gas fields in North America. The Company started oil and gas operations in the U.S. on November 1, 2009, with the purchase of a producing conventional oil and gas field, located in the Gulf Coast region of Texas, from Pioneer Natural Resources. In addition, they acquired interests in two properties located in the Gulf Coast region of Texas and one property in their Core Focus Area located in West Texas.
The Company lists on the OTC Bulletin Board. They have their headquarters in The Woodlands, Texas. They currently focus their oil and natural gas exploration, exploitation, and development operations on projects located in Colorado, New Mexico, and Texas.
Blacksands Petroleum acquired a 50 percent undivided leasehold Working Interest (WI) in approximately 3,300 acres located in South Colorado. Objectives include sandstone, carbonate and shale objectives.
The Company has an undivided leasehold WI in and to approximately 150,000 acres of land, located in the Pedregosa Basin (SW New Mexico). Blacksands Petroleum is exploring for potential commercially viable conventional and unconventional oil and gas hydrocarbon reservoirs in sandstones, carbonates and the Percha Shale.
Blacksands owns an undivided leasehold WI in four producing wells and approximately 9,000 acres in the Spraberry trend in West Texas. They also own an undivided leasehold WI in the Beech Creek field. The field is in northeastern Hardin County, Texas, northwest of the town of Silsbee.
The Company owns a 100 percent leasehold WI in and operates the J.E. Pettus Gas Unit in Cabeza Creek Field. The Cabeza Creek field is in north central Goliad County, Texas, approximately 7 miles southeast of the town of Goliad. In addition, they own an undivided interest in 1100 acres in south Zavala County, Texas. The acreage is in the current Eagle Ford Shale trend package.
Blacksands Petroleum, by way of their subsidiary NRG Assets Management, LLC (a Texas Limited Liability Company), is operating or intends to operate a majority of the producing and non-producing properties and leases they acquire. The Management Team manages the day-to-day operations. This includes all technical aspects of the properties, as part of the Company's long-term goals of cost control and production growth.
Blacksands Petroleum, Inc. (BSPE), closed at $1.26, up 0.80%, on 1,667 volume with 5 trades. The average volume for the last 60 days is 2,069 and the stock's 52-week low/high is $0.91/$4.25.
Authentidate Holding Corp. (ADAT)
SmarTrend Newsletters, The Online Investor, Profit Confidential, PennyInvest, PennyStockVille, StockEgg, MadPennyStocks, BullRally, StockRich, CoolPennyStocks, HotOTC, and Wall Street Resources reported earlier on Authentidate Holding Corp. (ADAT), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Authentidate Holding Corp. is a provider of secure web-based software applications and telehealth products and services for healthcare organizations. These enable healthcare organizations to coordinate care for patients and enhance related administrative and clinical workflows. The Company's products and services enable healthcare organizations to increase revenues, reduce costs and enhance patient care by eliminating paper and manual work steps from clinical and administrative processes. Authentidate Holding's has their headquarters in Berkeley Heights, New Jersey. The Company's shares trade on the NASDAQ Capital Market.
The design of all of their telehealth products and services are to reduce hospital readmissions and emergency visits by keeping patients with chronic illnesses on their care plans, managed and monitored by their healthcare providers. Their customers include leading health systems such as the Department of Veterans Affairs, national home care companies such as Gentiva and Apria, many hospital systems and ACOs.
Authentidate Holding's telehealth solutions combine patient vital signs monitoring with a web application that streamlines patient care management. Delivered as Software as a Service (SaaS), customers only require an Internet connection and web browser to access the Company's web-based applications.
The Company's Electronic House Call and Interactive Voice Response solutions monitor patient vital signs to improve patient care while reducing overall healthcare costs. Their Inscrybe® Hospital Discharge automates the hospital discharge planning process and improves hospital facility utilization through optimizing patient length-of-stay and bed turnover. Authentidate Holding's Inscrybe® Healthcare is a secure web-based service for healthcare entities that enables convenient, HIPAA-compliant document and information exchange.
Today, Authentidate Holding announced that they plan to introduce a mobile telehealth tablet and a telehealth software application (App) designed to address the needs of the growing mobile telehealth markets. They estimate that the market for remote patient monitoring solutions will grow to approximately $7 billion this year because of the impact of new programs designed to reduce patient care costs and the high hospital readmission rate of patients with chronic illnesses. These new products communicate automatically with Authentidate's robust web-based telehealth management software application.
Authentidate Holding Corp. (ADAT), closed Wednesday's trading session at $0.73, down 5.19%, on 137,400 volume with 167 trades. The average volume for the last 60 days is 28,926 and the stock's 52-week low/high is $0.5467/$1.64.
Dakota Plains Holdings, Inc. (DAKP)
Real Pennies reported earlier this month on Dakota Plains Holdings, Inc. (DAKP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Dakota Plains Holdings, Inc. focuses on developing and owning crude oil and related product transloading facilities, and the marketing and transporting of crude oil originating within the Williston Basin of North Dakota. Founded in 2008, the Company competes via their Joint Ventures through providing their customers with value-added benefits. These include a full-service transloading facility, competitive pricing and an optimal geographic location centrally located in Mountrail County, North Dakota. Listed on the OTC Bulletin Board, Dakota Plains Holdings has their corporate headquarters in Wayzata, Minnesota.
Through their wholly owned subsidiaries, the Company participates in a Joint Venture (JV) that markets crude oil purchased at the wellhead, a JV that transloads crude oil into rail cars at a facility owned by Dakota Plains in New Town, North Dakota, and a JV that transports crude oil by road through their trucking fleet. The organization of each JV is in the form of a limited liability company (LLC).
The North Dakota Bakken oil play was named the largest on-shore oil deposit in the United States by the United States Geological Society (USGS). New Town, North Dakota is centrally located in this play.
Dakota Plains Holdings completed their initial acquisition and build out of their New Town transloading facility in 2009. In 2011, the Company doubled the size of their facility. They brought the on-site tank car capacity to 160. The facility is fully operational. It is connected to Canadian Pacific's Class 1 Railway. This means of transportation to end-markets reflects Dakota Plains Holdings' and the industry's expectation that Williston Basin crude oil production will continue to grow for a number of years.
The Company's partners include World Fuel Services - a worldwide leader in the downstream marketing and financing of aviation, marine and ground transportation fuel products and related services. Partners also include Canadian Pacific (TSX: CP) (NYSE: CP), which operates a North American transcontinental railway providing freight transportation services, logistics solutions, as well as supply chain expertise.
Dakota Plains Holdings, Inc. (DAKP), closed Wednesday's trading session at $3.60, even for the day, on 121,408 volume with 58 trades. The average volume for the last 60 days is 124,385 and the stock's 52-week low/high is $1.75/$12.50.
Glen Eagle Resources, Inc. (GER.V)
We are highlighting Glen Eagle Resources, Inc. (GER.V), here at the QualityStocks Daily Newsletter.
Trading on the TSX Venture Exchange, Glen Eagle Resources, Inc. engages in the acquisition, exploration, and evaluation of mining properties. The Company explores primarily for phosphate and lithium and has interests in the Authier lithium project located in Lamotte, Quebec; and the Moose Lake and Lac Lisette phosphate properties located in the Lac St-Jean area, Quebec. Glen Eagle Resources has their headquarters in Montreal, Quebec.
The Company believes that their recent acquisitions of the Lac Lisette and Moose Lake phosphate properties further confirm their corporate mission of acquiring good assets in key sectors of the economy, notably lithium and phosphate. Furthermore, the Company has their Souart project (Net Smelter Return (NSR) - 2 percent Glen Eagle), located 40 kilometers east of Lebel-sur-Quevillon near Metanor, Bonterra and Eagle Hill. Glen Eagle Resources' commitment is to advance their mining projects towards economic viability.
Earlier this month, the Company reported the early results of the drilling program (2200 meters) carried out last fall on their Moose Lake phosphate project. Glen Eagle drilled 43 holes in 2012 for a total of 4559 meters. The drill holes were positioned on a 100 x 100 meters grid and generally reached a depth of 100 meters. The design of the drill program was to test the continuity of the deposit and the program was able to delineate a phosphate-rich ferrogabbro over 1.1 km in strike (East-West direction) and to a down dip length of 300 meters (North-South).
Yesterday, Glen Eagle Resources reported key data resulting from the Preliminary Economic Assessment (PEA) study recently completed by SGS Canada, Inc. The Company reports that, of note, an important advantage of the Authier Lithium Project is that the deposit occurs as a large and geometrically favorable pegmatite body (Li2O carrier). The pegmatite occurs near surface and continues to a depth of 175 meters at a 45°angle. The deposit remains open at depth with some of the highest grades occurring near the bottom.
Glen Eagle Resources, Inc. (GER.V), closed Wednesday's trading session at $0.34, even for the day, on 169,159 volume. The stock's 52-week low/high is $0.12/$0.37.
Inuvo, Inc. (INUV)
Alliance Advisors and Greenbackers reported recently on Inuvo, Inc. (INUV), Stock Traders Chat, PennyOmega, Stock Fortune Teller did previously, and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
Inuvo, Inc. is an Internet company that develops and markets browser based consumer applications and manages networks of websites. The Company's solutions help advertisers drive targeted transactions and acquire customers either on a pay-per-click (PPC), pay-per-lead or pay-per-sale basis by way of diverse marketing channels. The Inuvo Platform is the data hub for all of the Company's transactions, products and services. Inuvo has their corporate headquarters in New York, New York, and an office in Clearwater, Florida.
The Company has their Inuvo Search for website monetization. Inuvo Search, formerly ValidClick, is an exclusive program allowing approved publishers operating shopping search engines, local search engines, niche directory sites and other search-related sites to have pay-per-click sponsored ads on their site.
The Inuvo Platform also includes Affiliate Marketing; this is pay for performance with affiliate marketing platforms. In addition, the Company harnesses the best of the Web with Inuvo Brands. These brands include comparison-shopping to baby resources and business listings. Brands include Kowabunga®, BargainMatch®, Yellowise®, the ALOT portfolio of products, as well as BabytoBee®.
Inuvo Apps are the Company's various applications that allow users to create a unique user experience for their customers. This drives more traffic to their websites and helps them make more money from them. Inuvo provides them the opportunity to use the Company's flexible integrations.
In December 2012, Inuvo announced that their Board of Directors named Mr. Richard K. Howe as Chief Executive Officer. Mr. Howe will remain as the Company's Chairman of the Board. Earlier this month, the Company appointed Mr. Patrick Terrell to serve on their Board of Directors. Mr. Terrell is currently the managing member of both Terrell Group Management and PatRick Investments, LLC, private equity and real estate investment companies.
Today, Inuvo announced that their preliminary unaudited revenue for fiscal year 2012 was $53.3 million. This is up from $35.8 million in fiscal year 2011. Preliminary unaudited revenue for the fourth quarter of 2012 was $16.2 million. This represents an almost 5 percent increase over the $15.5 million in revenue reported in the third quarter of 2012. Preliminary unaudited revenue includes financial results from the acquisition of Vertro from March 2012 forward; prior years do not include Vertro financial results.
Inuvo, Inc. (INUV), closed Wednesday's trading at $0.92, up 12.20%, on 61,485 volume with 80 trades. The average volume for the last 60 days is 76,603 and the stock's 52-week low/high is $0.40/$2.12.
Marathon Patent Group, Inc. (ASMC)
Today we are reporting on Marathon Patent Group, Inc. (ASMC), here at the QualityStocks Daily Newsletter.
Marathon Patent Group, Inc. engages in the acquisition, development and monetization of intellectual property (IP) through the licensing of their own patent portfolio, the acquisition of additional IP, or through partnering with others to defend and enforce their patent rights. The Company formerly went by the name American Strategic Minerals Corp. They changed their name to Marathon Patent Group, Inc. on November 13, 2012. Incorporated in 2011, Marathon Patent Group is based in Alexandria, Virginia.
On November 20, 2012, American Strategic Minerals and Sampo IP LLC announced that they completed a merger. A majority of the Company's voting capital voted and authorized the Company to change their name to "Marathon Patent Group, Inc.". The expectation is that the name change will better align Marathon Patent Group with their new strategic direction. Marathon acquired the outstanding capital of Sampo IP LLC. Because of this transaction, they will own a patent portfolio.
In November, the Company also announced the naming of patent monetization veteran Mr. Doug Croxall as the Company's Chief Executive Officer and Chairman. Mr. Croxall was previously the Founder and CEO of LVL Patent Group, the patent holding company that owned the Sampo portfolio.
The Company's operating subsidiaries will generate revenue and related cash flows from the granting of a license for the rights to use the patented technologies, which their operating subsidiaries own or control. Marathon acquires patents and patent rights from the owners of the patents. The owners may include individual inventors, small technology companies and large corporations. The Company compensates the patent seller by either providing an upfront payment or by providing the patent seller participation in the revenue generated from the licensing activities, or a combination of both.
Marathon Patent Group's intention is to execute patent licensing agreements with corporations that benefit from the unauthorized use of their patented technologies via willing negotiations without the filing of patent infringement litigation, or through negotiations of patent license and settlement agreements in connection with the filing of patent infringement litigation.
Marathon has a portfolio consisting of three patents in the U.S. (and one open application) - U.S Patent #6,161,149, U.S Patent #8,015,495, and U.S Patent #6,772,229. These particular patents recite systems and methods for centralized communication by information and pushing notifications to group participants, providing links to portions of the stored information while restricting access to other portions of the stored information, and pushing notifications to user peripheral.
Marathon Patent Group, Inc. (ASMC), closed Wednesday's trading session at $0.70, even for the day, on 1,200 volume with 2 trades. The average volume for the last 60 days is 3,332 and the stock's 52-week low/high is $0.20/$1.15.
Coastal Pacific Mining Corp. (CPMCF)
StreetInsider, PennyStockVille, PennyInvest, CoolPennyStocks, MadPennyStocks, StockEgg, BullRally, HotOTC, StockRich, and Wall Street Grand reported earlier on Coastal Pacific Mining Corp. (CPMCF), and we highlight the Company, here at the QualityStocks Daily Newsletter.
Founded in 2007, Coastal Pacific Mining Corp. is an exploration stage company whose shares trade on the OTC Market's OTCQB. The Company's exploration mandate is to explore, develop and mine gold and/or silver-rich resources in North and South America. Coastal Pacific Mining will collaborate with companies having mineral properties suitable for development and production. Currently, the Company has agreements in place for properties in Ontario, Canada and the Province of Huancavelica, Peru. Coastal Pacific Mining is based in Calgary, Alberta.
The Company's philosophy is to participate with Companies who are in the later stage of exploration and are ready for development. Coastal Pacific has The Hotstone Gold Property. This Property consists of 5 claim blocks (approximately 120 hectares). It is 50 kilometers southeast of Chapleau, Ontario, and 130 km southwest of Timmins, Ontario in the heart of the Swayze Greenstone Belt, an extension of the famous Abitibi Greenstone Belt and the Porcupine and West Porcupine Gold Mining Camps. The Hotstone Gold Property is a drill ready gold prospect.
Additionally, their projects include The Santa Rita Property. The Property is in the District of Acobambilla, Province of Huancavelica, Department of Huancavelica, in the Republic of Peru; approximately 200 km southeast of Lima. A 43-101 Technical Report exists, which refers to a number of vein mineralizations characterized by elevated silver, lead and zinc content with averages of 290 g/t, 65 percent and 7 percent respectively. The Santa Rita, based on the engineering report, has open pit potential with an excess of 1,300,000 tons of mineralization identified.
Coastal Pacific Mining entered into an Option Agreement, in January of 2012, with Trio Gold on the Hotstone Gold Property. Coastal Pacific, along with D.L. Gibson (the Optionor) and Trio Gold of Calgary, Alberta, reached an arrangement to Option the Hotstone Gold property. The new Option Agreement supersedes and replaces the Option Agreement from March 29, 2011 between Coastal and D.L. Gibson.
Trio has the option to earn, upon fulfilling the terms of the Agreement, a 50 percent interest in the Hotstone Gold Property. Coastal Pacific Mining and the Optionor will each maintain a 25 percent interest in the Property, upon completion of the Option Agreement.
Coastal Pacific Mining Corp. (CPMCF), closed Wednesday's session at $0.006, up 20.00%, on 39,196 volume with 4 trades. The average volume for the last 60 days is 131,175 and the stock's 52-week low/high is $0.001/$0.0295.
Reg Technologies, Inc. (REGRF)
Bull Ventures reported previously on Reg Technologies, Inc. (REGRF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Headquartered in Richmond, British Columbia, Reg Technologies, Inc. engages in developing and building an axial vane-type rotary engine. It develops the RadMax™ rotary technology, used in the design of lightweight and high efficiency engines, compressors, as well as pumps. Incorporated in 1982, the Company lists on the OTC Bulletin Board and on the TSX Venture Exchange under the trading symbol RRE.V.
Reg Technologies owns the worldwide rights to the RadMax™ rotary technology and REGI U.S., Inc. (OTCBB: RGUS) owns the U.S. rights. The Company's goal is to license the RadMax™ technology and/or to participate in Joint Ventures (JVs) to manufacture specific RadMax™ applications. Reg Technologies and REGI U.S. are developing for commercialization the Rand Cam™/RadMax™ rotary technology.
The RadMax™ engine has only two unique moving parts, the vanes (up to 12) and the rotor. This is in comparison to the 40 moving parts in a simple four-cylinder piston engine. This particular design makes it possible to produce up to 24 continuous power impulses per one rotation that is vibration-free and extremely quiet. In addition, the engine has numerous capabilities allowing it to operate on fuels. These fuels include gasoline, natural gas, hydrogen, propane and diesel.
Yesterday, REGI U.S. and Reg Technologies announced that the 375 hp diesel RadMax™ engine is ready for assembly the week of January 28, 2013.
Mr. John Robertson, President of Reg Technologies and REGI U.S. stated, "I am very pleased with the work completed by Williams & White, Path Technologies, Robert Grisar, Dr. Allen MacKnight and Paul Porter."
Mr. Paul Porter, Chief Engineer, stated, "The fit checks were completed and all the parts have been reworked or corrected for assembly. The future tests will be to measure the first set of friction data and a baseline compression test without seals, and next with the seals. Future tests will be utilizing diesel and natural gas as the fuel."
Reg Technologies, Inc. (REGRF), closed Wednesday's trading session at $0.1458, down 10.00%, on 10,000 volume with 1 trade. The average volume for the last 60 days is 4,089 and the stock's 52-week low/high is $0.054/$0.19.
GlobalWise Investments, Inc. (GWIV)
The QualityStocks Daily Newsletter would like to spotlight GlobalWise Investments, Inc. (GWIV). Today, GlobalWise Investments, Inc. closed trading at $0.32, up 23.08%, on 17,802 volume with 9 trades. The stock’s average daily volume over the past 60 days is 10,253, and its 52-week low/high is $0.18/$1.87.
GlobalWise Investments, Inc. took some time out today to update markets on their recent debt to equity conversion, channel partnership, and market opportunity initiatives. The debt to equity conversion is a clear indication of the strength of the company's future growth potential and recent successes, boldly underscoring the confidence of GWIV's key investors and leading to a much stronger balance sheet with improved cash flow flexibility. Similarly the success of the shift to a channel sales model through 2011, in order to fully leverage the vitality of the company's unique software platform by kicking open whole new sales vectors, was covered. Fundamental advantages in the cloud-based Enterprise Content Management space should help to keep revenue growth and profitability accelerating into 2013.
GlobalWise Investments, Inc. (GWIV), via wholly-owned subsidiary Intellinetics, Inc., is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. The ECM industry continues to grow rapidly as a result of unrestricted proliferation of digital content within today's business environment. Leveraging its proprietary cloud-based computing software, GlobalWise is poised to capture a significant market share of this burgeoning industry.
GlobalWise's ECM service is delivered to customers via five unique delivery models which cover the spectrum of business needs: Cloud/Saas (Software as a Service), Hardware Vendor Integrated Service, Software Vendor Integrated Service, Premise (Client-Server), Hybrid (Premise & Cloud/Saas).This diversity gives advanced security & privacy features with an on-demand structure needed for large Tier 3 and Tier 4 businesses that are currently underserved by the market.
The Intellinetics platform defines a new industry benchmark and game-changing approach by combining advanced virtualization & automated content management with an open and service-oriented architecture using web services. The company provides strategies, tactics, and technologies used to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full time employee.
GlobalWise's management boasts a combined total of over 60 years in ECM leadership and industry experience. The ECM industry is expected to exceed $5.1 billion by 2013 with Gartner predicting a compound annual growth rate of 9.5%. IBM Market Insights predicts adoption of cloud computing to grow by 26% CAGR between 2010 through 2013. Leveraging management and key department heads, Intellinetics has a strong foundation from which to capture significant market share within the lucrative $149 billion Business Software & Services industry. Disclaimer
GlobalWise Investments Company Blog
GlobalWise Investments News:
GlobalWise Comments on Recent Balance Sheet Improvements, Channel Partners and Market Opportunities
GlobalWise CEO to Speak at Technology United Executive Conference
GlobalWise Launching Sales Campaign With Public Safety Market Leader Tiburon
Viscount Systems, Inc. (VSYS)
The QualityStocks Daily Newsletter would like to spotlight Viscount Systems, Inc. (VSYS). Today, Viscount Systems, Inc. closed trading at $0.12, up 21.21%, on 213,872 volume with 22 trades. The stock’s average daily volume over the past 60 days is 55,504, and its 52-week low/high is $0.0069/$0.13.
Viscount Systems, Inc. was pleased to announce reception of the coveted Microsoft “Be What’s Next” award today, for the company's participation in Microsoft Global Security’s Good Samaritan Project, which was submitted to their “What’s Next” competition. Viscount helped realize the goal of the Good Samaritan project, which sought to create a social network of employees that could reply to and assist in the event of emergencies, all through Viscount's innovative Freedom security platform, integrating Microsoft Kinect software and Microsoft Windows phones over an Azure Cloud app. Applying Microsoft’s leading edge Cloud and mobile platforms to the security industry opens huge new commercialization vectors for VSYS.
Viscount Systems, Inc. (VSYS) designs, manufactures, and services access control and security products such as door access control systems and emergency communications systems. The company's products have been installed in approximately 35,000 sites in over 30 countries, including prisons, schools, hospitals, and corporate offices.
Designing security systems since 1969, the company has developed strategic working relationships with leading equipment vendors to support its continued profitability and growth. Viscount has been consistently profitable for nearly 15 years and currently generates annual revenues of approximately $5 million.
Five hundred dealers help distribute Viscount's existing products throughout North America. This distribution network is not static as the company constantly pursues additional sales channels. Products are advertised in various print publications and regularly displayed at tradeshows as well. Direct marketing via training seminars also helps drive sales.
Viscount's management team has more than 60 years of combined experience in the development and production of electronic door control and telecommunication systems. Under this leadership, the SIA Convergence Solution of the Year accolade and Platinum Award for Emergency Response and Gold Award for Access Control at the Government Security Awards (GOVSEC) for 2011 have been presented to the company. Disclaimer
Viscount Systems, Inc. Company Blog
Viscount Systems, Inc. News:
Viscount Systems Receives Microsoft “Be What’s Next” Award
Viscount Systems Awarded New U.S. Government Contract
Viscount Systems To Secure Canadian Hotel Chain
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.77, off by 2.53%, on 3,500 volume with 3 trades. The stock’s average daily volume over the past 60 days is 1,654, and its 52-week low/high is $0.06/$3.10.
VistaGen Therapeutics, Inc. proudly announced the completion of the final Phase I safety study for their novel, orally available prodrug chronic neuropathic pain candidate, AV-101. Favorable bioavailability and pharmacokinetics endpoints stand out alongside the safe and well-tolerated results from the study, fielding important confirmation of AV-101's safeness and essentially sealing up the last step for the Phase I program. CEO of VSTA, Shawn K. Singh, JD, underscored the $8.8M in NIH funding and superb strategic support from Cato Research Ltd. in helping advance AV-101 to Phase II clinical development where the large, multiple neurological disease and condition markets come into play.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
VistaGen's lead drug candidate, AV-101, is in Phase Ib development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system.
Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
Vistagen Therapeutics Successfully Completes Final Phase 1 Safety Study of AV-101
VistaGen Therapeutics to Present at Noble Financial Capital Markets Ninth Annual Equity Conference
VistaGen Therapeutics Becomes Member of Centre for Commercialization of Regenerative Medicine Consortium
Bergamo Acquisition Corp. (BGMO)
The QualityStocks Daily Newsletter would like to spotlight Bergamo Acquisition Corp. (BGMO). Today, Bergamo Acquisition Corp. closed trading at $0.0289, up 7.04%, on 29,000 volume with 2 trades. The stock’s average daily volume over the past 60 days is 251,785, and its 52-week low/high is $0.01/$0.07.
Bergamo Acquisition Corp. (BGMO) is a global investor targeting a diversified portfolio of large corporate and middle-market companies for sole acquisition and co-investment alongside other sophisticated investors such as private equity funds, hedge funds, investment banks, and other institutions. The company has engaged investments in financial instruments and companies worldwide.
Alternative energy is a key focus of the company. Bergamo Acquisition has developed solar generators for cell phone towers, solar generators for home and industry applications, and solar operated tube well water pumping systems to meet the vast needs of emerging markets. The company’s turnkey solutions help developers, utilities, water districts, power plant owners, and industrial customers diversify their existing generation portfolio.
Bergamo Acquisition executes energy projects from concept through completion, offering design, construction management, and facility maintenance services. Together with pre-designed and packaged Balance of Plant and standardized Power Plant Control Modules, the company enables rapid project commissioning and provides an optimum balance between capital cost, plant performance, and operational and maintenance expenses.
The company’s technical team has been working with government officials, manufactures, and importers in Asia, Africa, and the Middle East to introduce its state-of-the-art technology. Investable funds are already in place to pursue investment opportunities in these and other countries. Bergamo Acquisition relies on its extensive network within the global institutional investment and banking industries to source the best opportunities. Disclaimer
Bergamo Acquisition Corp. Company Blog
Bergamo Acquisition Corp. News:
Bergamo Acquisition Corp. Signs Investment Agreement
Bergamo Acquisition Achieves Current Information Status on OTC Markets
Bergamo Acquisition’s CEO Does Radio Interview - Provides Update
GlobalWise Investments and its wholly owned subsidiary Intellinetics, a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age, today issued a press release providing an overview of recent debt to equity conversions, channel partnerships, and market opportunities.
“In 2012 we began to reap the benefits of our channel building efforts and market opportunities. While the numbers are still being finalized and will not be released until completion of our annual audit, I’m pleased with our results for the fourth quarter ended December 31, 2012 and expect to announce annual revenue growth in line with previously announced guidance of 50-60%. We also experienced stable gross profit margins and improvements in operating profit and net income for the quarter,” stated William J. “BJ” Santiago, CEO of GlobalWise.
“More importantly, we’re seeing a significant increase in sales activity within our existing channel partners,” he continued. “Based upon this activity and our current growth rate, we expect 2013 to be a defining year for our Company that could result in doubling or tripling our annual revenue. We also expect to announce the addition of new national and international channel partners in the near future and believe that we will see both accelerating revenue growth and profitability in 2013.”
On December 31, 2012, GlobalWise converted $945,729 of debt into 3,152,432 restricted shares of the company’s common stock at a price of $0.30 per share. This price was based on the closing price of GlobalWise common stock on December 28, 2012, the immediately preceding business day.
“The conversion of debt to equity underscores the confidence of our key investors in the recent successes and future growth potential of our business,” stated Kendall D. Gill, Chief Financial Officer of GlobalWise. “As a result, we have substantially improved our balance sheet, created more flexibility in our cash flow and improved the attractiveness of the Company for shareholders and potential investors. We’re currently in discussions with remaining debt holders and expect to announce additional equity conversions in the coming weeks.”
Last year’s focus was on the development of the channel partner program and on training and equipping new channel partners for success. As of the end of 2012, GlobalWise had 25 channel partners vs. 14 channel partners at the end of 2011. The company today reported the addition of hundreds of new customers during 2012 as a result of these efforts and expects to add significantly more in 2013 when these newly established sales channels are engaged for a full year.
“We began the transition to a channel sales model in 2011 as a part of a new strategy to leverage the strengths of our unique software platform by dramatically expanding our sales capability,” stated Santiago. “With the Intellivue™ software platform now fully cloud-enabled and the addition of 25 channel sales partners, our service model is highly scalable and our software can be delivered virtually anywhere in the world. By investing time, effort and resources in our channel sales program and training strategic partners in 2012 who are already selling software solutions into our target markets, we’re now able to efficiently access an expanding universe of potential clients.”
“Our software platform and delivery model are uniquely focused on providing ECM solutions to the underserved small-to-mid-sized business (SMB) market,” added the chief executive. “According to the most recent US Census Bureau data, there are approximately 100,000 businesses in the US with 100 employees or more and over 5,000,000 businesses with fewer than 100 employees.”
For more information, visit www.GlobalWiseInvestments.com
Viscount Systems, a leading-edge supplier of security systems and software, today reported it has been presented with a “Be What’s Next” award from Microsoft for its participation in the Microsoft Global Security’s Good Samaritan Project that was submitted to the Microsoft “What’s Next” competition.
The project’s purpose is to create a social network of employees to reply to and assist in the event of emergencies by using the Freedom security platform to integrate Microsoft Kinect software with Microsoft Windows phones through an Azure Cloud application. When the Kinect software identifies an emergency condition, Freedom Cloud software is used to identify staff in the relevant Freedom access control zone to send an emergency assistance message on their Windows phone.
“We were very pleased to have the opportunity to work on this project with Microsoft Global Security and to share in this honor,” stated Stephen Pineau, President and CEO of Viscount. “Viscount’s part of the Good Samaritan project focused on applying Microsoft’s leading edge Cloud and mobile platforms to the security industry. This project and our other R&D initiatives have resulted in the company filing numerous patents in the past year that relate to the Cloud, mobile devices, NFC, converged logical/physical identity management, smart cards, identity management and visitor management. As we begin to commercialize these products we believe that we are well positioned to become the leading provider of mobile and cloud solutions to the physical security industry.”
For more information on Viscount, visit www.viscount.com
VistaGen Therapeutics, a biotechnology company applying stem cell technology for drug rescue, predictive toxicology, and drug metabolism screening, excitedly reported today the successful completion of its final Phase 1 safety study of AV-101, a novel orally available prodrug candidate being developed for treatment of multiple conditions involving chronic neuropathic pain. AV-101 has been found to be safe and well tolerated, with favorable bioavailability and pharmacokinetics.
“This important confirmation of AV-101’s safety is the final step in our Phase 1 program for AV-101,” stated Shawn K. Singh, JD, VistaGen’s Chief Executive Officer. “With $8.8 million of funding from the National Institutes of Health (NIH) and outstanding strategic development and regulatory support from Cato Research Ltd., we have successfully completed the required studies enabling Phase 2 clinical development of AV-101 for multiple large market neurological diseases and conditions. In addition, recent data from the NIH suggest that the same neural pathway modified by AV-101 may be useful for treating depression. Launching a broad strategic collaboration to advance development and commercialization of AV-101 is among our key goals in 2013.”
Mark S. Wallace, MD, Chair of the Division of Pain Medicine, Department of Anesthesiology at UCSD and the principal investigator of the study, commented, “The primary safety and tolerability endpoints of the Phase 1 program were met. This is a very safe compound with no observed side effects. AV-101 is an exciting prodrug compound that acts through a promising mechanism to treat pain. I am excited to move this compound into Phase 2 studies for the treatment of pain.”
VistaGen’s final AV-101 Phase 1 safety study was a randomized, double-blind, placebo-controlled, dose-escalation clinical trial conducted at the University of California, San Diego (UCSD). The study involved three cohorts of healthy volunteers, each receiving multiple daily treatments of one of three dose levels of orally administered AV-101 over a 14-day period. The primary objectives of the study were to evaluate the safety, tolerability, and pharmacokinetics (PK) of three different daily doses of AV-101 compared to placebo controls. A total of 46 healthy volunteers completed the study. The oral administration of AV-101 was safe and well tolerated by all subjects at all three dose levels tested. In addition, the PK of AV-101 was fully characterized across the range of three dose levels in the study. The data indicate that AV-101 had good bioavailability and a favorable PK profile.
Aimed at multi-billion dollar neurological disease and disorders and depression markets, AV-101 is a novel, orally available prodrug that is converted in the brain into an active metabolite, 7-chlorokynurenic acid (7-Cl-KYNA), which regulates an important neurotransmitter in the brain called the N-methyl-D-aspartate (or NMDA) receptor. A synthetic analogue of kynurenic acid, a naturally occurring neural regulatory compound, 7-Cl-KYNA is one of the most potent and selective blockers of the regulatory GlyB-site of the NMDA receptor.
VistaGen’s AV-101 IND application covers clinical development for neuropathic pain. In addition to neuropathic pain, VistaGen expects the results of its Phase 1 clinical program to be useful for supporting the development of AV-101 for other neurological disorders including depression and epilepsy.
For more information, visit www.VistaGen.com
In its quest for new ways to use bio-engineered bacteria to manipulate the immune system as a superior tool for fighting cervical and other cancers as well as infectious diseases, Advaxis collaborates with top research centers around the world.
• National Cancer Institute – Advaxis works with the Institute’s Gynecologic Oncology Group to conduct a multi-center, Phase 2 clinical trial of ADXS-HPV immunotherapy, for patients with recurrent or refractory cervical cancer who have failed prior cytotoxic therapy.
• University of Pennsylvania – Advaxis works with the University’s School of Veterinary Medicine, collaborating with Dr. Nicola Mason to study the ADXS-HER2 construct for the treatment of canine osteosarcoma in large breed companion dogs.
• Cancer Research UK – The UK organization, dedicated to cancer research, is conducting a clinical trial to investigate the use of ADXS-HPV for the treatment of head and neck cancer.
• Montefiore Medical Center – Advaxis is working with Dr. Chandan Guha at the Albert Einstein College of Medicine and Montefiore Medical Center to develop the ADXS-PSA construct for the treatment of prostate cancer.
• National Cancer Institute – Advaxis has a Collaborative Research and Development Agreement (CRADA) with the Vaccine Section of the Institute for the development of Advaxis immunotherapies.
• Wistar Institute – Advaxis is collaborating with the Wistar Institute in Pennsylvania to explore the potential of FAP as a target for immune attack and as the basis for the development of an Advaxis immunotherapy.
• University of British Columbia – Advaxis is collaborating with the laboratory of Dr. Tobias Kollmann to develop Advaxis immunotherapies for the treatment of infectious disease and to develop new dosage forms.
• Karolinska Institutet – Advaxis is collaborating with the laboratory of Professor Marianne van Hage at the Karolinska Institutet in Stockholm, Sweden, to evaluate the potential of Advaxis immunotherapies to treat and prevent allergies in established scientific models of allergic diseases.
For additional information, visit www.Advaxis.com
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Advaxis, Inc. (ADXS) to Present at the 6th Annual OneMedForum
- Bergamo Acquisition Corp. (BGMO) Signs Investment Agreement
- Consorteum Holdings, Inc. (CSRH) Files Form 10-K Report With the Securities and Exchange Commission
- Cardium Therapeutics, Inc. (CXM) To Present At Biotech Showcase 2013 Investment Conference And Report On New Cardium Initiatives
- The Guitammer Company Inc. (GTMM) Insiders Acquire An Aggregate Of 156,000 GTMM Shares In Open Market Purchases
- GlobalWise Investments, Inc. (GWIV) Comments on Recent Balance Sheet Improvements, Channel Partners and Market Opportunities
- International Stem Cell Corp. (ISCO) Announces Positive Animal Efficacy Results in Liver Disease Program
- Loans4Less.com, Inc. (LFLS) Provides Preliminary Financial Results for Year Ended December, 31 2012
- TNI BioTech Inc. (TNIB) Acquires the Exclusive Rights to Low Dose Naltrexone and Other Opioid Antagonists for the Treatment of Inflammatory and Ulcerative Diseases of the Bowel
- Viaspace, Inc. (VSPC) Giant King Grass Energy Crop Growing in Hawaii
- Viscount Systems, Inc. (VSYS) Receives Microsoft “Be What’s Next” Award
- VistaGen Therapeutics, Inc. (VSTA) Successfully Completes Final Phase 1 Safety Study of AV-101